This CME activity reviews key clinical considerations for integrating lutetium-177 (177Lu)-prostate-specific membrane antigen (PSMA)-617 into the management of metastatic castration-resistant prostate cancer (mCRPC). Learners will examine the importance of appropriate patient selection using PSMA PET imaging criteria, the evolving role of radioligand therapy earlier in the disease course, and strategies for assessing treatment benefit beyond prostate-specific antigen response alone. The activity also discusses the risk-benefit profile of 177Lu-PSMA-617, including practical approaches for monitoring and managing common treatment-related adverse events.